TY - JOUR
T1 - Cytoreductive nephrectomy in patients presenting with advanced disease
T2 - Have we finally answered the question?
AU - Shapiro, Daniel D.
AU - Westerman, Mary E.
AU - Karam, Jose A.
AU - Wood, Christopher G.
N1 - Publisher Copyright:
© Wolters Kluwer Health, Inc. All rights reserved.
PY - 2020/9/1
Y1 - 2020/9/1
N2 - Determining the appropriate patients for cytoreductive nephrectomy (CN) has evolved with the integration of more effective systemic therapies for patients with metastatic renal cell carcinoma (mRCC). While previously considered to be first-line therapy for mRCC, CN has not demonstrated a significant survival advantage over systemic therapy in more recent randomized trials when compared with targeted therapy. Conversely, multiple observational studies demonstrate a therapeutic benefit for CN. This review synthesizes the current literature regarding patient selection for CN and further evaluates the role of CN in the current era of immune checkpoint inhibitor therapy. With careful patient selection, CN maintains an important role in the management of mRCC patients.
AB - Determining the appropriate patients for cytoreductive nephrectomy (CN) has evolved with the integration of more effective systemic therapies for patients with metastatic renal cell carcinoma (mRCC). While previously considered to be first-line therapy for mRCC, CN has not demonstrated a significant survival advantage over systemic therapy in more recent randomized trials when compared with targeted therapy. Conversely, multiple observational studies demonstrate a therapeutic benefit for CN. This review synthesizes the current literature regarding patient selection for CN and further evaluates the role of CN in the current era of immune checkpoint inhibitor therapy. With careful patient selection, CN maintains an important role in the management of mRCC patients.
KW - Checkpoint inhibitors
KW - cytoreductive nephrectomy
KW - renal cell carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85091324278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091324278&partnerID=8YFLogxK
U2 - 10.1097/PPO.0000000000000470
DO - 10.1097/PPO.0000000000000470
M3 - Review article
C2 - 32947306
AN - SCOPUS:85091324278
SN - 1528-9117
VL - 26
SP - 382
EP - 389
JO - Cancer Journal (United States)
JF - Cancer Journal (United States)
IS - 5
ER -